Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed
- PMID: 30262340
- DOI: 10.1016/j.eururo.2018.09.013
Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed
Comment on
-
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310. doi: 10.1177/1758835918788310. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30083254 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
